Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer.

The oncologist·2025
Same author

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve <i>EGFR</i>-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.

Cancer treatment reviews·2020
Same author

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.

American journal of clinical oncology·2015
Same author

Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2013
Same author

EGFR tyrosine kinase inhibitors: difference in efficacy and resistance.

Current oncology reports·2013

Related Experiment Video

Updated: May 25, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Beyond bevacizumab: antiangiogenic agents.

Shane Rogosin1, Alan B Sandler

  • 1Providence Oncology and Hematology Care Clinic-Southeast, Clackamas, OR, USA.

Clinical Lung Cancer
|February 3, 2012
PubMed
Summary

Antiangiogenic therapies targeting vascular endothelial growth factor (VEGF) show promise for non-small-cell lung cancer (NSCLC). However, resistance necessitates exploring novel anti-VEGF agents and other pathways for improved cancer treatment.

Area of Science:

  • Oncology
  • Cancer Research
  • Pharmacology

Background:

  • Angiogenesis is a key target for non-small-cell lung cancer (NSCLC) treatment.
  • Bevacizumab, a vascular endothelial growth factor (VEGF)-targeted antibody, improved survival in NSCLC patients when combined with chemotherapy (E4599 trial).
  • Responses to bevacizumab are often temporary, leading to inevitable resistance, highlighting the need for alternative antiangiogenic strategies.

Purpose of the Study:

  • To review current and emerging antiangiogenic agents targeting NSCLC.
  • To discuss the limitations of current therapies and the potential of novel therapeutic targets.
  • To explore the role of multitargeted receptor tyrosine kinase inhibitors (TKIs) and other agents in NSCLC treatment.

Main Methods:

  • Review of clinical development of antiangiogenic agents for NSCLC.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Related Experiment Videos

Last Updated: May 25, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

  • Analysis of multitargeted TKIs (sorafenib, cediranib, BIBF 1120) targeting VEGF, fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) pathways.
  • Inclusion of other novel agents targeting angiopoietin/TIE2, integrins, and the delta-like ligand-4/Notch pathway.

    • Main Results:

    • Bevacizumab plus chemotherapy demonstrated improved progression-free survival (PFS) and overall survival (OS) in NSCLC.
    • Several multitargeted TKIs have shown clinical activity in early-phase NSCLC trials, both as monotherapy and in combination with chemotherapy.
    • Emerging agents targeting various proangiogenic pathways represent promising future therapeutic options for NSCLC.

    Conclusions:

    • While bevacizumab offers survival benefits, its transient responses and resistance necessitate further research into novel antiangiogenic strategies for NSCLC.
    • Multitargeted TKIs and inhibitors of pathways like angiopoietin/TIE2 and delta-like ligand-4/Notch hold significant potential for improving NSCLC treatment outcomes.
    • Continued investigation into diverse antiangiogenic targets is crucial for developing more effective and durable therapies for NSCLC patients.